Michigan Medicine: 7-OH Ban Imminent — Addiction Specialists Urge Users to Seek Treatment Now

Why it matters

The impending DEA rescheduling of 7-OH — potentially effective as early as August 5, 2026 — is already driving dependent users toward treatment clinics. Abrupt loss of access without clinical support could push people toward more dangerous opioids including fentanyl.

The big picture

7-OH products, sold legally in most states for roughly two years, act on opioid receptors and have triggered addiction in users who initially sought relief from pain, anxiety, or opioid withdrawal. The DEA proposal to temporarily classify 7-OH as Schedule I — alongside heroin and LSD — followed sharp increases in poisonings, overdose deaths, and addiction cases. A 30-day public comment period that drew tens of thousands of responses just closed July 31, 2026, and the agency can act any day after August 5.

Key findings

• DEA proposed temporary Schedule I classification of 7-OH and three synthetic derivatives (mitragynine pseudoindoxyl, MGM-15, MGM-16) on July 1, 2026
• Scheduling order cannot take effect earlier than August 5, 2026, and would last two years with a possible one-year extension
• Threshold is products containing more than 1 mg of 7-OH or 0.05% by weight — natural leaf kratom products below threshold would not be affected
• Michigan House passed a bill banning all 7-OH and kratom products in March 2026; Michigan Senate has not yet acted
• Patients at University of Michigan Packard Health Clinic sought treatment in July specifically after vape shops warned them products were going away
• Buprenorphine treats 7-OH and kratom addiction the same way it treats opioid use disorder

What they say

"Regardless of the outcome of the DEA scheduling decision, the need for treatment access and education is increasing," said Dr. Eliza Hutchinson, who leads the Medications for Addiction Treatment team at Packard Health Clinic.

Bottom line

**With the 7-OH federal ban potentially days away, addiction specialists urge anyone physically dependent on 7-OH products to contact a healthcare provider now about buprenorphine treatment before access is cut off.**